Update SRA to SRIA 28 March 2017 Linda van Gaalen
Update SRA ‒ First SRA approved 2013 ‒ New CSA (EXEDRA): Add Innovation to SRA => SRIA ‒ Other WPs CSA will provide input ‒ Alignment necessary: ‒ with other SR(I)A’s ( eg. SRIA-IMI) ‒ stakeholders / industry ‒ national action plans ‒ WHO Global Action Plan
Important choices! ‒ SRIA specific for JPIAMR or - General SRIA (added value JPI indicated) ‒ Update or amendment?
Procedure Desk study existing SRIA’s 1. 2. Questionnaires: critical areas to reappraise (MB & SAB). 3. Workshops to prioritise research areas: roadmaps by SRIA pillar (WP 2 & EXEDRA WS) 4. Engagement with industry and stakeholders (WP3 & WP 4) 5. Draft 1 SRIA with SAB 6. Feedback: MB, Stakeholders & Industry 7. Draft 2 SRIA with SAB 8. Approval MB
What do we need ‒ MB approval on procedure ‒ Editorial board (?) ‒ Scope and strategic plan (CSA) ‒ List of stakeholders and industry to contact ‒ List of critical areas to reappraise from questionnaires ‒ List of prioritisation research areas from roadmaps ‒ Input from expert meeting ‒ Approval MB on SRIA ‒ Broad attention for SRIA through communication network
Planning and relation to EXEDRA activities M1-12 Relation What WP Task leader - Due date organiser (Month) Base of the update SRIA is Scope - strategic plan JPIAMR 2 ISCII - Spain 3 scope and strategic plan EXEDRA Opinion of SAB and MB Questionnaire to MB - SAB on 5.1 ZON - Netherlands 5 current SRA SAB meeting ZON - Netherlands 6 Alignment with other SRA's Desk study & consultation partner 5.1 ZON - Netherlands 7 (WHO and others) countries Work Shop Environmental SRC - Sweden 9 Work Shop Virtual Institute DLR - Germany 9 Work Shop Interventions ISCII - Spain 10 MB Meeting SRC - Sweden 10 CSA EXEDRA meeting SRC - Sweden 10 SAB meeting ZON - Netherlands 12 Editorial board Establish editorial board 5.1 ZON - Netherlands 12 for Update SRA SAB - MB - SH? Engagement stakeholders / Mapping and analysis international 3 DLR - Germany 12 other countries collaboration for Update SRA Engagement stakeholders / Strengthen dialogue with industry 4.2 ANR - France 12 other countries for Update SRA
Planning and relation to EXEDRA activities M13-24 Relation What WP Task leader - Due date organiser (month) Engagement alignment strategy with national policy 4.1 SRC - Sweden 15 stakeholders / other makers and international SH countries Draft 1 SAB development Draft 1 5.1 ZON - Netherlands 16 jan-march 2018 Stakeholder and industry Expert meeting on Draft 1 5.1 ZON - Netherlands 17 feedback April-May 2018 Draft 2 SAB development Draft 2 5.1 ZON - Netherlands 18 May - June 2018 Feedback Participants Distribute draft 2 SRIA 5.1 ZON - Netherlands 18 on draft 2 SRIA Final SRIA SAB development Final SRIA 5.1 ZON - Netherlands 19 Sept -Oct 2018 Final approval of Distribute final SRIA 5.1 ZON - Netherlands 23 member countries SRIA October 2018 Update SRIA publication of the SRIA 5.1 ZON - Netherlands 24 Use communication Promotion SRIA 6.2 SRC - Sweden 12-48 channels
Questions to take into account 1. Which innovation aspects will be an addition to the present SRA? 2. How does the SRA relate and align with industry and initiatives such as IMI, etc? 3. How can translational research be stimulated? 4. How can key networks of academic and industrial excellence be developed and involved? 5. What are priorities in the current pillars? 6. What are key areas for implementation of the SRA? 7. How can we measure or define “value added” to the SRIA? 8. What are other key areas or instruments we should think of?
Current strategic research priorities SRA A. Therapeutics B. Diagnostics C. Surveillance D. Transmission E. Environment F. Interventions
Objectives WHO Global Action Plan AMR 1. Improve awareness and understanding of antimicrobial resistance through effective communication, education and training 2. Strengthen the knowledge and evidence base through surveillance and research 3. Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures 4. Optimize the use of antimicrobial medicines in human and animal health 5. Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions
Questions 1. General or specific SRIA? 2. Update or amendment? 3. Approval procedure 4. Editorial board (M12)? Yes / No? If yes; any suggestions? • MB, SAB, Stakeholders, Others @: abr@zonmw.nl
Recommend
More recommend
